GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocytogen Pharmaceuticals (Beijing) Co Ltd (FRA:I54) » Definitions » Forward PE Ratio

Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) Forward PE Ratio : 33.35 (As of May. 04, 2025)


View and export this data going back to 2022. Start your Free Trial

What is Biocytogen Pharmaceuticals (Beijing) Co Forward PE Ratio?

Biocytogen Pharmaceuticals (Beijing) Co's Forward PE Ratio for today is 33.35.

Biocytogen Pharmaceuticals (Beijing) Co's PE Ratio without NRI for today is 231.92.

Biocytogen Pharmaceuticals (Beijing) Co's PE Ratio (TTM) for today is 143.57.


Biocytogen Pharmaceuticals (Beijing) Co Forward PE Ratio Historical Data

The historical data trend for Biocytogen Pharmaceuticals (Beijing) Co's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocytogen Pharmaceuticals (Beijing) Co Forward PE Ratio Chart

Biocytogen Pharmaceuticals (Beijing) Co Annual Data
Trend 2024-12
Forward PE Ratio
32.50

Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
2024-12
Forward PE Ratio 32.50

Competitive Comparison of Biocytogen Pharmaceuticals (Beijing) Co's Forward PE Ratio

For the Biotechnology subindustry, Biocytogen Pharmaceuticals (Beijing) Co's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biocytogen Pharmaceuticals (Beijing) Co's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biocytogen Pharmaceuticals (Beijing) Co's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Biocytogen Pharmaceuticals (Beijing) Co's Forward PE Ratio falls into.


;
;

Biocytogen Pharmaceuticals (Beijing) Co Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Biocytogen Pharmaceuticals (Beijing) Co  (FRA:I54) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Biocytogen Pharmaceuticals (Beijing) Co Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Biocytogen Pharmaceuticals (Beijing) Co's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Biocytogen Pharmaceuticals (Beijing) Co Business Description

Traded in Other Exchanges
Address
12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other advanced solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.

Biocytogen Pharmaceuticals (Beijing) Co Headlines

No Headlines